J Y Blay, C Cropet, S Mansard, Y Loriot, C De La Fouchardière, J Haroche, D Topart, D Tougeron, B You, A Italiano, V Le Brun-Ly, J M Ferrero, N Penel, M Fabbro, X Troussard, D Malka, I Ray-Coquard, S Leboulleux, A Fléchon, E Maubec, J Charles, S Dalle, S Taieb, G C T E Garcia, A M Mandache, N Colignon, M Gavrel, F Nowak, N Hoog Labouret, C Mahier Aït Oukhatar, C Gomez-Roca
BACKGROUND: BRAF inhibitors are approved in BRAFV600 -mutated metastatic melanoma, non-small-cell lung cancer (NSCLC), Erdheim-Chester disease (ECD), and thyroid cancer. We report here the efficacy, safety, and long-term results of single-agent vemurafenib given in the AcSé vemurafenib basket study to patients with various BRAF-mutated advanced tumours other than BRAFV600 -mutated melanoma and NSCLC. PATIENTS AND METHODS: Patients with advanced tumours other than BRAFV600E melanoma and progressing after standard treatment were eligible for inclusion in nine cohorts (including a miscellaneous cohort) and received oral vemurafenib 960 mg two times daily...
November 1, 2023: ESMO Open